Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Updates of Hematological Findings and Complications in Novel Coronavirus...
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Updates of Hematological Findings and Complications in Novel Coronavirus Pneumonia

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (25 July 2023) | Viewed by 9671

Special Issue Editor

Dr. Alessandra D’Abramo

E-Mail Website
Guest Editor
Highly Contagious Infectious Diseases Unit, National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani IRCCS, 00149 Rome, Italy
Interests: infectious diseases; emerging infectious diseases; tropical and neglected diseases

Special Issue Information

Dear Colleagues,

The overall burden of mortality and morbidity associated with the COVID-19 pandemic continues to increase. In most cases, the cause of death has been linked to respiratory failure, sepsis, heart failure, renal injury, or coagulopathy. It has been well-established that COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. A thorough understanding of different systemic manifestations and complications of SARS-CoV-2 is important for better clinical management. Hematologic abnormalities, such as lymphopenia, thrombocytopenia, elevated D-dimer, elevated fibrinogen, elevated fibrinogen degradation products, and cytokines, such as IL-6, can be an early indicator for hospitalization, disease severity, and outcome helping clinicians to make timely clinical decisions. Hematologic complications, such as venous thrombosis, pulmonary embolism, arterial thrombosis, have been noted to be directly related to the high mortality from COVID-19. An attempt to understand the pathophysiology of the various hematologic abnormalities including cytokine storm, hypercoagulable state, and some rare presentations of this disease, therefore, becomes imperative. As the pathophysiology and complications associated with COVID-19 continue to unfold, further basic science research in the areas of pathophysiology and randomized control trials are needed for successful management of this pandemic.

Dr. Alessandra D’Abramo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • hematologic features
  • cytokines
  • coagulation
  • hypercoagulabilty
  • inflammation
  • hematologic complications

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 780 KiB  
Article
Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia
by Juan Mora-Delgado, Cristina Lojo-Cruz, Patricia Rubio Marín, Eva María Menor Campos and Alfredo Michán-Doña
J. Clin. Med. 2023, 12(3), 928; https://doi.org/10.3390/jcm12030928 - 25 Jan 2023
Viewed by 3380
Abstract
Some patients with COVID-19 have complex hypercoagulable abnormalities that are related to mortality. The optimal dosage of low molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia is still not clear. Our objective is to evaluate the effects of adapting the dosage of [...] Read more.
Some patients with COVID-19 have complex hypercoagulable abnormalities that are related to mortality. The optimal dosage of low molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia is still not clear. Our objective is to evaluate the effects of adapting the dosage of low molecular weight heparin to thrombotic and bleeding risk scales in this setting. We performed a cohort, retrospective, observational, and analytical study at the Hospital Universitario of Jerez de la Frontera, with patients admitted with SARS-CoV-2 pneumonia from 1 October 2020 to 31 January 2021. They were classified according to whether they received prophylactic, intermediate, or therapeutic doses of enoxaparin. The primary endpoint was intrahospital mortality. Secondary endpoints were the need for invasive ventilation, thromboembolic events, bleeding, and the usefulness of thrombotic and bleeding scales. After binary logistic regression analysis, considering confounding variables, it was found that the use of enoxaparin at therapeutic doses was associated with lower mortality during admission compared to prophylactic and intermediate doses (RR 0.173; 95% CI, 0.038–0.8; p = 0.025). IMPROVE bleeding risk score correlated with a higher risk of minor bleeding (RR 1.263; 95% CI, 1.105–1.573; p = 0.037). In adult hospitalized patients with SARS-CoV-2 pneumonia presenting elevated D-dimer and severe proinflammatory state, therapeutic doses of enoxaparin can be considered, especially if bleeding risk is low according to the IMPROVE bleeding risk score. Full article
(This article belongs to the Special Issue Clinical Updates of Hematological Findings and Complications in Novel Coronavirus Pneumonia)
►▼ Show Figures

Graphical abstract

18 pages, 2006 KiB  
Article
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
by Nuria Muñoz-Rivas, Jesús Aibar, Cristina Gabara-Xancó, Ángela Trueba-Vicente, Ana Urbelz-Pérez, Vicente Gómez-Del Olmo, Pablo Demelo-Rodríguez, Alberto Rivera-Gallego, Pau Bosch-Nicolau, Montserrat Perez-Pinar, Mónica Rios-Prego, Olga Madridano-Cobo, Laura Ramos-Alonso, Jesús Alonso-Carrillo, Iria Francisco-Albelsa, Edelmira Martí-Saez, Ana Maestre-Peiró, Manuel Méndez-Bailón, José Ángel Hernández-Rivas and Juan Torres-Macho
J. Clin. Med. 2022, 11(19), 5632; https://doi.org/10.3390/jcm11195632 - 24 Sep 2022
Cited by 12 | Viewed by 3262
Abstract
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients [...] Read more.
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (p = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. Trial RegistrationClinicalTrials.gov Identifier (NCT04730856). Edura-CT registration number: 2020-004279-42. Full article
(This article belongs to the Special Issue Clinical Updates of Hematological Findings and Complications in Novel Coronavirus Pneumonia)
►▼ Show Figures

Figure 1

11 pages, 990 KiB  
Article
Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study
by Paul Simon, Pierrick Le Borgne, François Lefevbre, Lauriane Cipolat, Aline Remillon, Camille Dib, Mathieu Hoffmann, Idalie Gardeur, Jonathan Sabah, Sabrina Kepka, Pascal Bilbault, Charles-Eric Lavoignet and Laure Abensur Vuillaume
J. Clin. Med. 2022, 11(16), 4903; https://doi.org/10.3390/jcm11164903 - 21 Aug 2022
Cited by 12 | Viewed by 2458
Abstract
(1) Introduction: In the present study, we investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) as a marker of severity and mortality in COVID-19 infection. (2) Methods: Between 1 March and 30 April 2020, we conducted a multicenter, retrospective cohort study of patients [...] Read more.
(1) Introduction: In the present study, we investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) as a marker of severity and mortality in COVID-19 infection. (2) Methods: Between 1 March and 30 April 2020, we conducted a multicenter, retrospective cohort study of patients with moderate to severe coronavirus 19 (COVID-19), all of whom were hospitalized after being admitted to the emergency department (ED). (3) Results: A total of 1035 patients were included in our study. Neither lymphocytes, platelets or PLR were associated with disease severity. Lymphocyte count was significantly lower and PLR values were significantly higher in the group of patients who died, and both were associated with mortality in the univariate analysis (OR: 0.524, 95% CI: (0.336–0.815), p = 0.004) and (OR: 1.001, 95% CI: (1.000–1.001), p = 0.042), respectively. However, the only biological parameter significantly associated with mortality in the multivariate analysis was platelet count (OR: 0.996, 95% CI: (0.996–1.000), p = 0.027). The best PLR value for predicting mortality in COVID-19 was 356.6 (OR: 3.793, 95% CI: (1.946–7.394), p < 0.001). (4) Conclusion: A high PLR value is however associated with excess mortality. Full article
(This article belongs to the Special Issue Clinical Updates of Hematological Findings and Complications in Novel Coronavirus Pneumonia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop